Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
166 hedge funds and large institutions have $372M invested in Verve Therapeutics in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 64 increasing their positions, 47 reducing their positions, and 30 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 47
17% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 30
2% more funds holding
Funds holding: 163 → 166 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6.97% less ownership
Funds ownership: 97.62% → 90.65% (-7%)
43% less call options, than puts
Call options by funds: $576K | Put options by funds: $1M
66% less capital invested
Capital invested by funds: $1.08B → $372M (-$712M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$20.5M |
| 2 |
BlackRock
New York
|
+$7.84M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.69M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$3.14M |
| 5 |
Goldman Sachs
New York
|
+$2.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$19.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.3M |
| 4 |
State Street
Boston,
Massachusetts
|
-$11M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$9.28M |
VERV Hedge Fund Activity: Q2 2024 in Review
166 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2024, worth a combined $372M — down 66% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new VERV positions and 30 closed out — a net gain of 5 holders — while 64 added to existing stakes and 47 trimmed.
The largest buyer was Millennium Management, adding an estimated $20.5M. The largest seller was ARK Investment Management, cutting an estimated $19.5M.
- 166 institutional investors held Verve Therapeutics (VERV) as of Q2 2024, up from 163 in Q1 2024.
- Funds reported $372M of Verve Therapeutics stock for Q2 2024, down 66% quarter-over-quarter.
- 35 funds opened new Verve Therapeutics positions in Q2 2024 and 30 closed out, a net change of +5 holders.
- The largest Verve Therapeutics buyer in Q2 2024 was Millennium Management, an estimated $20.5M added.
- The largest Verve Therapeutics seller in Q2 2024 was ARK Investment Management, an estimated $19.5M sold.
Based on aggregated 13F filings for Q2 2024.